Trial Information

Summary: SWOG S0325: A Phase IIB Study of Molecular Responses to Imatinib at Standard or Increased Doses for Previously Untreated Patients with Chronic Myelogenous Leukemia in Chronic Phase

You have been asked to participate in this research study because you have untreated Philadelphia chromosome positive Chronic Myelogenous Leukemia (CML) that is in chronic phase (CP). The purpose of this study is to learn if the higher dose of imatinib is better than and just as safe as the standard dose in treating CML. Your participation in this study is expected to last 12 months for treatment and approximately 1 year for follow-up.

Patient Inclusion/Exclusion Criteria:

- See http://clinicaltrials.coh.org for additional information.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: October 6, 2008 at 2:28:25 PM